BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 16233969)

  • 1. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
    Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
    Domest Anim Endocrinol; 2006 Jul; 31(1):63-75. PubMed ID: 16233969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism.
    Cook AK; Bond KG
    J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
    Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R
    J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
    Vaughan MA; Feldman EC; Hoar BR; Nelson RW
    J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs.
    Bell R; Neiger R; McGrotty Y; Ramsey IK
    Vet Rec; 2006 Aug; 159(9):277-81. PubMed ID: 16946310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of trilostane treatment on circulating thyroid hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism.
    Kenefick SJ; Neiger R
    J Small Anim Pract; 2008 Mar; 49(3):139-43. PubMed ID: 18086154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentrations of cortisol and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
    Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
    Vet Rec; 2008 Oct; 163(16):477-81. PubMed ID: 18931355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism.
    Wenger M; Sieber-Ruckstuhl NS; Müller C; Reusch CE
    Am J Vet Res; 2004 Sep; 65(9):1245-50. PubMed ID: 15478772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of canine Alopecia X with trilostane.
    Cerundolo R; Lloyd DH; Persechino A; Evans H; Cauvin A
    Vet Dermatol; 2004 Oct; 15(5):285-93. PubMed ID: 15500480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment.
    Boretti FS; Holzthüm J; Reusch CE; Sieber-Ruckstuhl NS
    Schweiz Arch Tierheilkd; 2016 Sep; 158(9):631-638. PubMed ID: 27655162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of baseline cortisol, endogenous ACTH, and cortisol/ACTH ratio to monitor trilostane treatment in dogs with pituitary-dependent hypercortisolism.
    Burkhardt WA; Boretti FS; Reusch CE; Sieber-Ruckstuhl NS
    J Vet Intern Med; 2013; 27(4):919-23. PubMed ID: 23701195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cortisol precursors for the diagnosis of pituitary-dependent hypercortisolism in dogs.
    Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
    Vet Rec; 2008 May; 162(21):673-8. PubMed ID: 18503066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
    Ruckstuhl NS; Nett CS; Reusch CE
    Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs.
    Macfarlane L; Parkin T; Ramsey I
    Vet Rec; 2016 Dec; 179(23):597. PubMed ID: 27803375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism.
    Galac S; Buijtels JJCWM; Mol JA; Kooistra HS
    Vet J; 2010 Jan; 183(1):75-80. PubMed ID: 19042143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cortisol Concentrations in Well-Regulated Dogs with Hyperadrenocorticism Treated with Trilostane.
    Midence JN; Drobatz KJ; Hess RS
    J Vet Intern Med; 2015; 29(6):1529-33. PubMed ID: 26374943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of trilostane for the treatment of alopecia X in Alaskan malamutes.
    Leone F; Cerundolo R; Vercelli A; Lloyd DH
    J Am Anim Hosp Assoc; 2005; 41(5):336-42. PubMed ID: 16141187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenocorticotropic hormone, but not trilostane, causes severe adrenal hemorrhage, vacuolization, and apoptosis in rats.
    Burkhardt WA; Guscetti F; Boretti FS; Ivos Todesco A; Aldajarov N; Lutz TA; Reusch CE; Sieber-Ruckstuhl NS
    Domest Anim Endocrinol; 2011 Apr; 40(3):155-64. PubMed ID: 21194873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
    Arenas C; Melián C; Pérez-Alenza MD
    J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008-2012).
    Woolcock AD; Bugbee AC; Creevy KE
    J Am Vet Med Assoc; 2016 Apr; 248(7):814-21. PubMed ID: 27003023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.